Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Total Debt (2019 - 2025)

Harmony Biosciences Holdings' Total Debt history spans 7 years, with the latest figure at $163.7 million for Q4 2025.

  • For Q4 2025, Total Debt fell 8.7% year-over-year to $163.7 million; the TTM value through Dec 2025 reached $163.7 million, down 8.7%, while the annual FY2025 figure was $163.7 million, 8.7% down from the prior year.
  • Total Debt for Q4 2025 was $163.7 million at Harmony Biosciences Holdings, down from $168.5 million in the prior quarter.
  • Across five years, Total Debt topped out at $197.1 million in Q3 2023 and bottomed at $163.7 million in Q4 2025.
  • The 5-year median for Total Debt is $191.6 million (2022), against an average of $186.7 million.
  • The largest annual shift saw Total Debt increased 2.82% in 2023 before it decreased 8.7% in 2025.
  • A 5-year view of Total Debt shows it stood at $192.0 million in 2021, then decreased by 0.18% to $191.6 million in 2022, then increased by 1.0% to $193.6 million in 2023, then fell by 7.39% to $179.3 million in 2024, then decreased by 8.7% to $163.7 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Total Debt are $163.7 million (Q4 2025), $168.5 million (Q3 2025), and $172.1 million (Q2 2025).